Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease-Reference-Cited by-同舟云学术

Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease

Published:2016-11-08 Issue:2 Volume:22 Page:133-144
ISSN:1354-750X
Container-title:Biomarkers
language:en
Short-container-title:Biomarkers

Author:

Román Irene D.¹,Cano-Martínez David¹,Lobo María Val T.²,Fernández-Moreno María Dolores¹,Hernández-Breijo Borja¹,Sacristán Silvia³,Sanmartín-Salinas Patricia¹,Monserrat Jorge⁴,Gisbert Javier P.⁵,Guijarro Luis G.¹

Affiliation:

1. Department of Systems Biology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Alcalá, Alcalá de Henares, Spain;

2. Department of Biomedicine and Biotechnology, University of Alcalá, Alcalá de Henares, Spain;

3. Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Madrid, Spain;

4. Department of Medicine, University of Alcalá, Alcalá de Henares, Spain;

5. Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

Funder

Universidad de Alcalá/Comunidad de Madrid

Comunidad de Madrid

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Clinical Biochemistry,Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/1354750X.2016.1252950

Reference49 articles.

1. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease

2. Intestinal Cell Proliferation and Senescence Are Regulated by Receptor Guanylyl Cyclase C and p21